Leadership
Team

Our experienced leadership team is passionate about applying cutting-edge science to the development of life-changing therapies. Cancer has no borders. Neither do we.

Executive Team

JVO John V. Oyler Chairman, Co-Founder & CEO

John V. Oyler is our Chairman and Co-Founder, and has served as our Chief Executive Officer and a member of our Board of Directors since 2010. From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1997 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology‑focused biopharmaceutical company. Mr. Oyler joined the Board of Directors of the Biotechnology Innovation Organization (BIO) in 2019 and is a member of its Health Section Governing Board. He began his career as a management consultant at McKinsey & Company. Mr. Oyler received his B.S. from Massachusetts Institute of Technology and MBA from Stanford University.

Xiaodong Wang, Ph.D., Chairman of Scientific Advisory Board & Co-Founder Xiaodong Wang, Ph.D. Chairman of Scientific Advisory Board & Co-Founder

Xiaodong Wang, Ph.D., is our Co-Founder and has served as the Chairman of our Scientific Advisory Board since 2011. Dr. Wang became a member of our Board of Directors in February 2016. Dr. Wang has served as the founding Director of the National Institute of Biological Sciences in Beijing since 2003 and became its Director and Investigator in 2010. Previously, he was a Howard Hughes Medical Institute Investigator from 1997 to 2010 and held the position of the George L. MacGregor Distinguished Chair Professor in Biomedical Sciences at the University of Texas Southwestern Medical Center in Dallas, Texas from 2001 to 2010. In 2004, Dr. Wang founded Joyant Pharmaceuticals, Inc., a venture capital-backed biotechnology company focused on the development of small molecule therapeutics for cancer. Dr. Wang received his Ph.D. in Biochemistry from the University of Texas Southwestern Medical Center and B.S. in Biology from Beijing Normal University. Dr. Wang has been a member of the National Academy of Science, USA, since 2004 and a foreign associate of the Chinese Academy of Sciences since 2013.

Xiaobin Wu, Ph.D. Xiaobin Wu, Ph.D. General Manager of China & President of BeiGene, Ltd.

Xiaobin Wu, Ph.D., joined BeiGene in 2018 as our General Manager of China and President of BeiGene, Ltd. Dr. Wu was previously the Country Manager of Pfizer China and the Regional President of Pfizer Essential Health for Greater China from October 2009 to April 2018. Under Dr. Wu’s leadership, Pfizer expanded its portfolio and organization, grew sales meaningfully, initiated a range of innovative marketing programs, and established its position as a leading multinational pharmaceutical company in China. Prior to Pfizer, Dr. Wu served as President and Managing Director of Wyeth China and Hong Kong from August 2004 to October 2009. Before Wyeth, Dr. Wu was General Manager of Bayer Healthcare in China from 2001 to 2004. He started his career in 1992 in sales and marketing with Bayer in Germany. Dr. Wu received a Ph.D. in Biochemistry and Pharmacology and a master’s degree in Molecular Biology from the University of Konstanz in Germany.

Howard Liang, Ph.D. Howard Liang, Ph.D. CFO & Chief Strategy Officer

Howard Liang, Ph.D., has served as our Chief Financial Officer and Chief Strategy Officer since July 2015. Prior to joining us, from 2005 to 2015, Dr. Liang was at Leerink Partners LLC, a leading investment bank specializing in the healthcare industry, where he served as a Managing Director and Head of Biotechnology Equity Research. Dr. Liang served as a Senior Biotechnology Analyst at two full-service investment banks: A.G. Edwards Inc., from 2004 to 2005, and JMP Securities, from 2003 to 2004. From 2000 to 2003, Dr. Liang served as an Associate Analyst at Prudential Securities, where he covered major and specialty pharmaceuticals. Before Wall Street, from 1992 to 2000, Dr. Liang was with Abbott Laboratories, where he was a Senior Scientist and a member of one of the pharmaceutical industry’s leading structure-based discovery teams. During his career as a scientist, Dr. Liang authored a review and 13 papers including six in Nature, Science, and Proceedings of the National Academy of Sciences. Dr. Liang received his B.S. in Chemistry from Peking University and both his MBA and Ph.D. in Biochemistry and Molecular Biology from the University of Chicago.

Yong Ben Yong (Ben) Ben, M.D. CMO, Immuno-Oncology

Yong (Ben) Ben, M.D., MBA, joined BeiGene in February 2019 as Chief Medical Officer, Immuno-Oncology, bringing in more than 20 years of experience in oncology. Prior to joining us, Dr. Ben served as Chief Medical Officer at San Diego-based biotech company BioAtla and concurrently as co-founder, Chief Medical Officer & President at Himalaya Therapeutics focusing on oncology drug development of BioAtla’s pipeline in China. Previously, he was global clinical leader of immuno-oncology clinical development at AstraZeneca, leading the approval of PD-L1 durvalumab in urothelial cancer. Dr. Ben’s career highlights also include his work on the approval of ixazomib in multiple myeloma at Millennium Pharmaceuticals and the approval of axitinib in renal cancer at Pfizer. Throughout his career, Dr. Ben has led wide-spectrum clinical development efforts from Phase 1 to Phase 3 trials from strategy planning, and study execution, to BLA/NDA submissions. He started his career as a surgical oncologist at Peking Union Medical College Hospital and completed a postdoctoral fellowship at California Pacific Medical Center. Dr. Ben received his medical degree from Norman Bethune College of Medicine and his MBA from the University of California, San Diego.

Denise Denise Dettore VP, Human Resources, U.S. and Europe, & Co-Lead Global HR

Denise Dettore joined BeiGene as our Vice President, Human Resources for the U.S. and Europe, and Co-Lead of our Global HR function in January 2018. Ms. Dettore brings 20 years of HR leadership in high growth and biotech companies throughout Silicon Valley, including: Genentech, Jazz Pharmaceuticals, Hewlett-Packard, Agilent Technologies as well as Electronic Arts. Most recently, during her time at Jazz Pharmaceuticals, Ms. Dettore led the HR Business Partner team as the organization grew from 250 employees to 1,150 employees in four years. Ms. Dettore also led strategic, global, organization-wide initiatives enabling Jazz to rapidly scale. Ms. Dettore is an active volunteer in the San Francisco community, having served as a member of the Board of Directors at Edgewood Center for Children and Families for 10 years. Denise has a M.S. in Human Resources and is also a Cambridge-certified English as a Second Language (ESL) instructor.

Eric Hedrick, M.D. Eric Hedrick, M.D. Chief Advisor

Eric Hedrick, M.D., has served as an advisor to BeiGene since 2015 and is currently Chief Advisor for the company. Prior to this, he served as the Chief Medical Officer of Epizyme, Inc. from 2012 to 2014. Prior to Epizyme, he served in several senior clinical development roles at Pharmacyclics, including Interim Chief Medical Officer, responsible for the development of Imbruvica® (ibrutinib) from 2010 to 2012. From 2000 to 2009 he held several clinical development positions at Genentech, Inc. where he was responsible for multiple aspects of the drug development and post-marketing programs for Rituxan® (rituximab) and Avastin® (bevacizumab). Prior to his time at Genentech, Dr. Hedrick was an Associate Attending Physician at Memorial Sloan-Kettering Cancer Center, where he focused on clinical research in non-Hodgkin's lymphoma, myelodysplastic syndromes, multiple myeloma and hematopoietic growth factors. He served as Resident and Chief Resident in Internal Medicine at Boston City Hospital and completed a fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center. Dr. Hedrick is Board certified in Medical Oncology and Internal Medicine. Dr. Hedrick received his M.D. from the University of Maryland School of Medicine and a B.A. in Biology from Boston University.

Jane Huang, M.D. Jane Huang, M.D. CMO, Hematology

Jane Huang, M.D., joined our Company in September 2016 as our Chief Medical Officer, Hematology. Prior to joining us, Dr. Huang served as the Vice President, Clinical Development at Acerta Pharma from 2015 to 2016, where she oversaw global clinical development of the BTK inhibitor, acalabrutinib. Previously, she worked at Genentech from 2005 to 2015, serving most recently as Group Medical Director, where she played a leading role in drug development programs for several molecules at all stages of development, including venetoclax and obinutuzumab. She is also an Adjunct Clinical Assistant Professor in Oncology at Stanford University, specializing in Thoracic Oncology. Dr. Huang received her Bachelor of Science degree in Biological Sciences from Stanford University and her M.D. from University of Washington School of Medicine. She is board certified in hematology, oncology, and internal medicine, and she completed her residency in Internal Medicine and fellowships in Hematology and Oncology at Stanford University.

Jonathan Liu, Ph.D., DVM Jonathan Liu, Ph.D., DVM SVP, Bio-Manufacturing

Jonathan Liu, Ph.D., DVM, joined BeiGene in 2018 as Senior Vice President, Bio-Manufacturing. He joined BeiGene from Johnson & Johnson (J&J) where he held the position of Head of China Pharmaceutical Development & Manufacturing Sciences (PDMS), responsible for PDMS operations of biologicals, small molecule drugs and vaccine development in the Asia Pacific region. Prior to joining J&J Dr. Liu spent more than 20 years in the industry and has led many drug development projects in CMC, manufacturing, R&D and production facility management, and has contributed to the successful launch, clinical studies and/or other major milestones for ReFacto®,BENEFIX®,FluMist®, ACAM2000® and 20 other drug products for Pfizer, Sanofi, AstraZeneca and Novartis. His ACAM project team completed the entire drug development cycle from discovery to commercialization and national strategic stockpiling in less than five years. In addition, he is a co-author of Quality by Design for Vaccine, a white paper to the U.S. FDA on behalf of the vaccine industry. He has authored or co-authored prolifically, on subjects including the highest volumetric vaccine manufacturing process, and more than 150 scientific book chapters, lectures, journal articles in Nature, Proceedings of the National Academy of Sciences (PNAS) and has more than 20 inventions patented in the U.S., Europe, Japan, Australia and other countries.

Dr. Liu holds Ph.D. and DVM degrees from Queen’s University in Canada, and from the Hunan Agricultural University in China, respectively. He completed his post-doctoral fellowship in Harvard Medical School. He has been a member of Advisory Board or board of directors for the United States National Center of Therapeutics Manufacturing, investment firms, biotech companies, various trade organizations and scientific journal review boards.

Lily Liu Lily Liu VP, Head of Marketing, Greater China

Lily Liu joined BeiGene in June 2019 as VP, Head of Marketing, Greater China, with over two decades of experience in the pharmaceutical industry. Prior to BeiGene, Ms. Liu was VP, Head of the Specialty Care business unit at Takeda in China, responsible for turning around the Enatone business and introducing the new product Ninlaro, which made the China national reimbursement drug list (NRDL) only five months after approval. Previously, she served as Sales Head of Oncology, Immunology, and Rare Disease at Pfizer, taking Xalkori to become the number one product for Pfizer Oncology and also successfully launched Xeljanz. Before that, Ms. Liu held a range of positions in marketing and market access at Janssen China and at their U.S. headquarters. She has a medical degree in Pediatric Medicine from Capital Medical University.

Josh Neiman Josh Neiman Head, U.S. Commercial

Josh Neiman joined BeiGene in July 2018 as Head of U.S. Commercial. Mr. Neiman is responsible for building and leading the commercial team and operations that will bring BeiGene’s innovative medicines to patients in the U.S. Mr. Neiman has broad U.S. commercial and global oncology experience that spans marketing, sales, market access, lifecycle management, data and analytics. Most recently, Mr. Neiman was Vice President, Marketing at Flatiron Health from 2014 through its acquisition by Roche in 2018. Previously, Mr. Neiman served in a progression of commercial leadership roles at Onyx Pharmaceuticals and Genentech, Inc. where he was responsible for multiple aspects of commercialization for Kyprolis® (carfilzomib), Rituxan® (rituximab), Gazyva® (obinutuzumab), and Herceptin® (trastuzumab). Early in his career, Mr. Neiman worked as a research associate in drug discovery at Tao Biosciences and Plexxikon. Mr. Neiman received his MBA from the Kellogg School of Management at Northwestern University and his B.A. from the University of California, Berkeley, in Molecular and Cell Biology.

Scott Samuels, Esq. Scott Samuels, Esq. SVP, General Counsel

Scott Samuels, Esq., has served as our Senior Vice President, General Counsel since May 2017. Prior to joining us, Mr. Samuels served as Assistant General Counsel and Acting General Counsel and Secretary at ARIAD Pharmaceuticals, Inc., from 2016 through its acquisition in 2017 by Takeda Pharmaceuticals. Previously, Mr. Samuels spent 17 years in private practice at the law firm Mintz Levin, including nine years as a partner in the firm’s life sciences practice, where he specialized in securities law, corporate governance, and business development and corporate financing transactions. Mr. Samuels began his career as a law clerk in the U.S. District Court in Philadelphia. Mr. Samuels received his J.D. from George Mason University and his Bachelor of Arts in Philosophy from Cornell University.

Michael Schoen Michael Schoen Chief of Staff to the CEO & SVP, Business Operations

Michael H. Schoen joined BeiGene in August 2017 and is the Chief of Staff to CEO John Oyler and Senior Vice President, Business Operations. Prior to joining BeiGene he was Managing Director & Head of Latin America & Caribbean Debt Capital Markets for Scotiabank. Mr. Schoen also worked at Credit Suisse, DLJ, and J.P. Morgan in their respective Emerging Markets groups. Mr. Schoen graduated from the Massachusetts Institute of Technology with a B.S. in Management from the Sloan School of Management. He is also the Vice Chairman of the Board of Directors of the HealthCare Chaplaincy Network, a global health care nonprofit organization that offers spiritual care-related information and resources, and professional chaplaincy services in hospitals, other health care settings, and online.

Guillaume Vignon, Ph.D. Guillaume Vignon, Ph.D. SVP, Business Development

Guillaume Vignon, Ph.D., joined BeiGene in 2018 as our Senior Vice President, Business Development. Dr. Vignon formerly held the position of Vice President, Global Head Oncology and Immuno-Oncology Licensing & Business Development at Merck KGaA/EMD Serono. In this position, Dr. Vignon led a team of business development professionals responsible for structuring and negotiating terms of licensing agreements for oncology and immuno-oncology assets from discovery to commercial stage. As part of his mandate, he provided business development expertise and strategic input into the Oncology strategy. Throughout his career at Merck KGaA, Dr. Vignon forged and successfully established several strategic partnerships in the fields of Immuno-Oncology, Oncology, Companion Diagnostic, and Antibody Discovery with academia, biotech, and pharma. Dr. Vignon holds a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6/ Institut Pasteur, Paris, France and an MBA from Hult International Business School, Cambridge, MA.

Gary Wang Gary Wang VP, Human Resources, APAC, & Co-Lead Global HR

Gary Wang has served as our Vice President of Human Resources, APAC, and Co-Lead of our Global HR function since April 2018. Prior to joining BeiGene Gary was at Johnson & Johnson from 2010 to 2018, where he served various HR leadership positions. From 2017 to 2018, he was the head of the HR business unit of the company’s R&D organizations and J&J Innovation Asia Pacific. From 2012 to 2017, he was Head of Talent Acquisition China when he built up the China Talent Acquisition team of J&J. From 2010 to 2012, he was the senior HR Business Partner in Janssen, the pharmaceutical company of J&J. Prior to healthcare industry at Johnson & Johnson, Gary spent about 10 years in technology industry, from 2008 to 2010, he served as the head of HR Asia at The MathWorks, a Boston based software company. From 2004 to 2008, Gary was at Symantec, where he was the HR manager of China Development Center. From 2001 to 2004, Gary was at the BEA Systems Inc, as the HR supervisor. Gary received his Bachelors’ Degree of Economics from Beijing Institute of Tourism and his EMBA from the Tsinghua University.

Lai Wang, Ph.D. Lai Wang, Ph.D. SVP, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development

Lai Wang, Ph.D., is our Senior Vice President, Head of Global Research, Clinical Operation & Biometrics and APAC Clinical Development. Dr. Wang joined BeiGene in the early days of the company, 2011. His role has changed over the years within the organization, initially heading the biomarker and in vivo pharmacology groups. In 2013, he supported the clinical programs in the role of clinical biomarkers and translational research. In 2016, he was appointed as the head of China development, responsible for the clinical development in Asian-pacific region. Prior to joining BeiGene, Dr. Wang was the director of research at Joyant Pharmaceuticals, a biotech company based in Dallas, Texas. Dr. Wang received his B.S. from Fudan University and Ph.D. from University of Texas Health Science Center at San Antonio, and had post-doc training with Dr. Xiaodong Wang at Howard Hughes Medical Institute. Dr. Wang had over 20 years of experience in oncology field and over 10 years of experience in pharmaceutical industry on both research and development.

Anita Wu Anita Wu Chief Commercial Officer, Greater China

Anita Wu joined BeiGene in June 2019 as Chief Commercial Officer, Greater China, bringing more than 20 years of industry experience to the Company. Most recently, Ms. Wu served as General Manager of the Specialty Care business unit at Sanofi China. While at Sanofi, she drove impressive revenue growth. While there she successfully launched Aubagio, a multiple sclerosis product, which set records at Sanofi for new product launch timeline and launch excellence. Ms. Wu played an important role in shaping rare disease policy as the RDPAC Rare Disease group co-chair and a key member of the China Rare Disease Alliance. Prior to Sanofi, Ms. Wu held several leadership positions at AstraZeneca China, including Head of the Diabetes business unit, as well as sales and marketing roles in the Oncology business unit. There, she successfully launched Iressa in first-line and set up the first dedicated biomarker testing team in China to solidify the drug’s leadership in lung cancer. Ms. Wu also worked for Pfizer in China and the U.S., Genzyme, and Eli Lilly. She holds a BS in Environmental Engineering from Shanghai University.

Wendy Yan Wendy Yan SVP, Global Head of Regulatory Affairs

Wendy Yan is our Senior Vice President and has served as Global Head of Regulatory Affairs since 2014. From 1996 to 2014, Ms. Yan held senior Regulatory Affairs positions at GlaxoSmithKline, AstraZeneca, and Bayer. She was the Director, Head of Regulatory Affairs at GSK. At Bayer, she served as the Head of Regulatory Affairs, then Global Regulatory Strategist at Global R&D Center. From 1988 to 1995, Ms. Yan was the chief pharmacist at Beijing Drug Control Institute, a subordinate organization of former CFDA. Ms. Yan received her M.D. from Beijing Traditional Chinese Medicine University and MBA from Staffordshire University (UK).

Todd Yancey Todd Yancey, M.D. SVP, Global Medical Affairs & New Market Development

Todd Yancey, M.D., is our Senior Vice President, Global Medical Affairs and New Market Development. Dr. Yancey joined BeiGene in February 2017 as Senior Vice President, Global Clinical Development for Immuno-Oncology where he was instrumental in developing the global solid tumor clinical program and organization. Dr. Yancey has been a physician for over 30 years and has spent the majority of that time in roles of increasing seniority in international biotechnology Clinical Development and Medical Affairs. He has served in a leadership role for the development or launch of seven registered Oncology therapeutics. Previously, Dr. Yancey was Group Vice President of Global Medical Affairs at BioMarin; SVP of Global Medical Affairs at Clovis Oncology; VP of Global Medical Affairs at Medivation; and SVP of Clinical Development at Onyx. Dr. Yancey received his M.D., from the University of Virginia School of Medicine and his Bachelor of Arts in Biology and Psychology also from the University of Virginia. He completed his residency in Internal Medicine at The New York Hospital, Memorial Sloan Cancer Center and his fellowship in General Internal Medicine and HIV infection at Cornell University.  

Board of Directors

Timothy Chen Timothy Chen Director

Timothy Chen has served as a member of our Board of Directors since February 2016. Mr. Chen has served as the Chairman of Foxconn Industrial Internet Company since January 2018 and as the Corporate Vice President of Hon Hai Technology Group and President of Asia Pacific Telecom since January 2016. He was the President of Telstra International Group from November 2012 to December 2015. He has also served as Chairman of the board of Autohome Inc. since 2012. Previously, Mr. Chen was a partner of a China Opportunities Fund within GL Capital Group from 2010 to 2012. He was the CEO of National Basketball Association China from 2007 to 2010, the Corporate Vice President of Microsoft and the CEO of its Greater China region from 2003 to 2007, and the Corporate Vice President of Motorola and the Chairman and President of Motorola (China) Electronics from 2001 to 2003. Before Motorola, he was the CEO of 21CN Cybernet, a company listed on the Hong Kong Stock Exchange, from 2000 to 2001. Prior to 2000, Mr. Chen spent eight years in China with Motorola, including serving as the General Manager responsible for the sales and marketing for the Greater China Cellular Infrastructure Division. He also spent nine years with AT&T Bell Laboratories in the United States. Mr. Chen holds an MBA degree from the University of Chicago, a master’s degree in both computer science and mathematics from Ohio State University, and a bachelor’s degree from Chiao Tung University.

Donald W. Glazer Donald W. Glazer Director

Donald W. Glazer has served as a member of our Board of Directors since February 2013. Mr. Glazer has served as a member of the Board of Trustees of GMO Trust, a mutual fund group, since 2000 and as the Chairman of the Board of GMO Trust since 2005. Mr. Glazer was a Co-Founder and Secretary, and from 2002 until 2010, Vice Chairman, of Provant, Inc., a provider of performance improvement training solutions. From 1992 to 1995 Mr. Glazer was President of Mugar/Glazer Holdings and from 1992 to 1993 served as Vice Chairman—Finance of New England Television Corp and WHDH-TV, Inc. From 1997 to the present, Mr. Glazer has served as Advisory Counsel to Goodwin Procter LLP. From 1970 to 1978 Mr. Glazer was an associate and from 1978 to 1992 a partner at Ropes & Gray LLP, a Boston law firm. At Ropes & Gray, Mr. Glazer chaired the firm’s Emerging Companies Group. Mr. Glazer was also a Lecturer in Law at Harvard Law School from 1978 to 1991, teaching a course called The Business Lawyer. Mr. Glazer is a former member of the boards of directors of Environics Inc.; Kronos Incorporated; Reflective Technologies, Inc.; and Teleco Oilfield Services Inc. Mr. Glazer received his A.B. from Dartmouth College; J.D. from Harvard Law School, where he was an editor of the Harvard Law Review; and L.L.M. from the University of Pennsylvania Law School. Additionally, Mr. Glazer is a co-author of both Glazer and FitzGibbon on Legal Opinions, Third Edition (Aspen Publishers) and Massachusetts Corporation Law & Practice, Second Edition (Aspen Publishers).

Michael Goller Michael Goller Director

Michael Goller has served as a member of our Board of Directors since April 2015. Mr. Goller has been with Baker Bros. Advisors LP since 2005 and currently serves as a Partner. Prior to joining Baker Bros., Mr. Goller served as an Associate of JPMorgan Partners, LLC where he focused on venture investments in the life sciences sector from 1999 to 2003. Mr. Goller began his career as an investment banker with Merrill Lynch and Co. from 1997 to 1999. Mr. Goller holds a B.S. in Molecular and Cell Biology from The Pennsylvania State University and Master’s degrees in each of Biotechnology (School of Engineered and Applied Sciences) and Business Administration (Wharton School) from the University of Pennsylvania.

Ranjeev Krishana Ranjeev Krishana Director

Ranjeev Krishana has served as a member of our Board of Directors since October 2014. Mr. Krishana has worked at Baker Bros. Advisors LP from 2011 to the present and currently serves as Head of International Investments. Prior to joining Baker Bros., Mr. Krishana held a series of commercial, strategy, and business development leadership roles for Pfizer, Inc.’s pharmaceutical business across a variety of international regions and markets, including Asia, Eastern Europe, and Latin America. Mr. Krishana was at Pfizer from 2003 to 2007 and from 2008 to 2011. From 2008 to 2010, Mr. Krishana was based in Beijing, China, where he served as a Senior Director and a member of the Pfizer China Leadership Team. Mr. Krishana began his career as a strategy consultant at Accenture plc. Mr. Krishana holds a B.A. in Economics and Political Science from Brown University, and a Masters of Public Policy from Harvard University.

Thomas Malley Thomas Malley Director

Thomas Malley has served as a member of our Board of Directors since January 2016. Mr. Malley has served as President of Mossrock Capital, LLC, a private investment firm, since May 2007. Mr. Malley worked for Janus Mutual Funds in positions of increasing responsibility from April 1991 to May 2007. From January 1999 to May 2007, Mr. Malley served as the portfolio manager of the Janus Global Life Sciences Fund and also led the Janus healthcare team of analysts. From 1991 to 1998, Mr. Malley served as an equity analyst for Janus covering, among others, healthcare and biotechnology stocks. Mr. Malley has been a director of Kura Oncology, Inc. since 2015 and a director of Kiniksa Pharmaceuticals since 2016. Previously, he served as a director of OvaScience, Inc., a public biopharmaceutical company, from 2012 to 2017; Synageva BioPharma Corp., a public biopharmaceutical company, from 2006 to 2015, until its acquisition by Alexion Pharmaceuticals, Inc.; Puma Biotechnology, Inc., a public biopharmaceutical company, from 2011 to 2015; and Cougar Biotechnology, Inc., a public biopharmaceutical company, from 2007 to 2009, until its acquisition by Johnson and Johnson. Mr. Malley holds a B.S. in Biology from Stanford University.

JVO John V. Oyler Chairman, Co-Founder & CEO

John V. Oyler is our Chairman and Co-Founder, and has served as our Chief Executive Officer and a member of our Board of Directors since 2010. From 2005 to 2009, Mr. Oyler served as President and Chief Executive Officer of BioDuro, LLC, a drug discovery outsourcing company, which was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr. Oyler served as Chief Executive Officer of Galenea Corp., a biopharmaceutical company dedicated to the discovery of novel therapies for central nervous system diseases, which initially were developed at Massachusetts Institute of Technology. From 1997 to 2002, Mr. Oyler was a Founder and the President of Telephia, Inc. which was sold to The Nielsen Company in 2007. From 1997 to 1998, Mr. Oyler served as Co-Chief Executive Officer of Genta Incorporated (NASDAQ: GNTA), an oncology‑focused biopharmaceutical company. Mr. Oyler joined the Board of Directors of the Biotechnology Innovation Organization (BIO) in 2019 and is a member of its Health Section Governing Board. He began his career as a management consultant at McKinsey & Company. Mr. Oyler received his B.S. from Massachusetts Institute of Technology and MBA from Stanford University.

Jing-Shyh (Sam) Su Jing-Shyh (Sam) Su Director

Jing-Shyh (Sam) Su has served as a member of our Board of Directors since April 2018. Mr. Su retired from Yum! Brands, Inc. (“Yum! Brands”) in May 2016, where he served as Vice Chairman of the Board of Directors, and was the Chairman and CEO of the company’s China division. During Mr. Su’s 26 years with Yum! Brands, its China division grew from just four restaurants to over 7,000 to become the largest multinational restaurant chain in China, contributing more than half of Yum! Brands’ world-wide revenues in 2015. Mr. Su started his career with Yum! Brands in 1989 as KFC International’s director of marketing for the North Pacific region. In 1993, he became vice president of North Asia for both KFC and Pizza Hut. Mr. Su was named president of Greater China for Tricon Global Restaurants International upon Pepsi’s spin-off of the restaurant business in 1997. Before joining Yum! Brands, Mr. Su worked with Procter & Gamble in Germany and Taiwan. Mr. Su currently serves as a director of Li Ning Company Limited, and of the board of directors of Peet’s Coffee China. Mr. Su earned his undergraduate degree at the National Taiwan University, an M.Sc. degree in Chemical Engineering at Pennsylvania State University, and an MBA at the Wharton School of the University of Pennsylvania.

Xiaodong Wang, Ph.D., Chairman of Scientific Advisory Board & Co-Founder Xiaodong Wang, Ph.D. Chairman of Scientific Advisory Board & Co-Founder

Xiaodong Wang, Ph.D. is our Co-Founder and has served as the Chairman of our Scientific Advisory Board since 2011. Dr. Wang became a member of our Board of Directors in February 2016. Dr. Wang has served as the founding Director of the National Institute of Biological Sciences in Beijing since 2003 and became its Director and Investigator in 2010. Previously, he was a Howard Hughes Medical Institute Investigator from 1997 to 2010 and held the position of the George L. MacGregor Distinguished Chair Professor in Biomedical Sciences at the University of Texas Southwestern Medical Center in Dallas, Texas from 2001 to 2010. In 2004, Dr. Wang founded Joyant Pharmaceuticals, Inc., a venture capital-backed biotechnology company focused on the development of small molecule therapeutics for cancer. Dr. Wang received his Ph.D. in Biochemistry from the University of Texas Southwestern Medical Center and B.S. in Biology from Beijing Normal University. Dr. Wang has been a member of the National Academy of Science, USA, since 2004 and a foreign associate of the Chinese Academy of Sciences since 2013.

Michael Nuoqing Yi Michael Nuoqing Yi Director

Michael Nuoqing Yi has served as a member of our Board of Directors since October 2014. Mr. Yi is a Partner at Hillhouse Capital. He has worked with Hillhouse since the inception of the firm in 2005. Prior to joining Hillhouse, Mr. Yi was an Equity Research Analyst at China International Capital Corporation. Mr. Yi’s work at Hillhouse includes investments in the healthcare and consumer sectors in both its public and private equity portfolios. He received a B.S in Engineering from Shanghai Maritime University, as well as an MBA from University of Southern California.

Scientific Advisory Board

Ron Levy, M.D. Ron Levy, M.D.
  • Professor of Medicine, Director of Lymphoma Program, Former Chief of Division of Oncology at Stanford
  • Member of National Academy of Sciences & Institute of Medicine
  • More than 20 years research on mAb to B cells; first to successfully treat human lymphoma with a monoclonal antibody, and went on to make important contributions to the development of Rituxan® (rituximab), for treatment of patients with resistant low-grade lymphomas
Neal Rosen, M.D., Ph.D. Neal Rosen, M.D., Ph.D.
  • Member of Department of Medicine and Head of Developmental Therapeutics at Memorial Sloan-Kettering Cancer Center
  • Professor of Pharmacology, Cell Biology and Medicine at Cornell University
  • Played important role in developing tyrosine kinase-mediated signaling inhibitors and pioneered concept that cancer cells are dependent on cellular machinery for protein folding
Charles Sawyers, M.D. Charles Sawyers, M.D.
  • President-elect of the AACR; former President of the American Society of Clinical Investigation
  • Serves on the National Cancer Institute’s Board of Scientific Counselors
  • Member of the Institute of Medicine of the National Academy of Sciences
David Schenkein, M.D. David Schenkein, M.D.
  • Agios (AGIO) Chief Executive Officer
  • Adjunct Attending Physician in Hematology at Tufts Medical Center
  • Member of the board of directors for the Biotechnology Industry Organization (BIO)
  • Formerly at Genentech, Millennium Pharma
  • Served as Adjunct Clinical Professor of Medical Oncology at Stanford
Jedd Wolchok, M.D., Ph.D. Jedd Wolchok, M.D., Ph.D.
  • Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSK)
  • Associate Director of the Ludwig Center for Cancer Immunotherapy and the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair for Clinical Investigation at MSK
  • Associate Director of the CRI Scientific Advisory Council
  • Co-editor of the journal Cytotherapy
  • M.D. and a Ph.D. from New York University
Steven Young, Ph.D. Steven Young, Ph.D. Acting Head of Medicinal Chemistry
  • 28 years of medicinal chemistry pharmaceutical R&D experience
  • Led chemistry research teams that delivered the widely prescribed HIV drugs efavirenz and raltegravir to AIDS patients
  • Former VP and Head of Medicinal Chemistry at Merck’s West Point laboratory
  • Delivered numerous compounds across a wide range of therapeutic areas into Phase I, II and III clinical programs
  • Ph.D. in Organic Chemistry from the University of California at Berkeley
  • B.S. from Stevens Institute of Technology

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept